Effects of growth hormone administration on protein dynamics and substrate metabolism during 4 weeks of dietary restriction in obese women

Helene Nørrelund, Jens Børglum, Jens Otto Lunde Jørgensen, Bjørn Richelsen, Niels Møller, K Sreekumaran Nair, Jens Sandahl Christiansen

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

OBJECTIVE: Treatment of obesity with very low calorie diet (VLCD) is complicated by protein loss. We evaluated the effects of coadministration of GH on protein turnover, substrate metabolism, and body composition in VLCD treated obesity. DESIGN AND PATIENTS: Fifteen obese women underwent 4 weeks of very low calorie diet (VLCD) in parallel with GH treatment (n = 7) or placebo (n = 8). MEASUREMENTS: Protein metabolism and total glucose turnover were isotopically assayed. Plasma concentrations of amino acids were determined by an HPLC system. Estimated rates of lipid and glucose oxidation were obtained by indirect calorimetry. Fat free mass was determined by DEXA- scan. RESULTS: Protein breakdown decreased in both groups (tyrosine flux μmol/h): -12% ± 3 (GH) vs. -9% ± 3 (placebo)). Phenylalanine degradation in relation to phenylalanine concentration decreased by 9% in the GH group, whereas an increase of 8% was observed in the placebo group (P = 0.1). Plasma concentrations of several amino acids were significantly decreased in the placebo group, while urea excretion decreased in the GH group. A decrease in FFM was found in placebo treated patients (2.14% ± 1.9 (GH) vs. -3.54% ± 1.6 (placebo), P < 0.05). Rates of lipid oxidation tended to be increased by GH treatment (lipid oxidation (mg/minutes): 79.7 ± 5.9 (GH) vs. 64.6 ± 5.9 (placebo), P = 0.1). CONCLUSION: During dietary restriction GH primarily seems to conserve protein by a reduced hepatic degradation of amino acids.

Original languageEnglish (US)
Pages (from-to)305-312
Number of pages8
JournalClinical Endocrinology
Volume52
Issue number3
DOIs
StatePublished - 2000

Fingerprint

Growth Hormone
Placebos
Caloric Restriction
Proteins
Phenylalanine
Lipids
Amino Acids
Obesity
Glucose
Indirect Calorimetry
Photon Absorptiometry
Body Composition
Tyrosine
Urea
Therapeutics
Fats
High Pressure Liquid Chromatography
Liver

ASJC Scopus subject areas

  • Endocrinology

Cite this

Effects of growth hormone administration on protein dynamics and substrate metabolism during 4 weeks of dietary restriction in obese women. / Nørrelund, Helene; Børglum, Jens; Jørgensen, Jens Otto Lunde; Richelsen, Bjørn; Møller, Niels; Nair, K Sreekumaran; Christiansen, Jens Sandahl.

In: Clinical Endocrinology, Vol. 52, No. 3, 2000, p. 305-312.

Research output: Contribution to journalArticle

Nørrelund, Helene ; Børglum, Jens ; Jørgensen, Jens Otto Lunde ; Richelsen, Bjørn ; Møller, Niels ; Nair, K Sreekumaran ; Christiansen, Jens Sandahl. / Effects of growth hormone administration on protein dynamics and substrate metabolism during 4 weeks of dietary restriction in obese women. In: Clinical Endocrinology. 2000 ; Vol. 52, No. 3. pp. 305-312.
@article{ef316c2d169f46308355b9e78c33020b,
title = "Effects of growth hormone administration on protein dynamics and substrate metabolism during 4 weeks of dietary restriction in obese women",
abstract = "OBJECTIVE: Treatment of obesity with very low calorie diet (VLCD) is complicated by protein loss. We evaluated the effects of coadministration of GH on protein turnover, substrate metabolism, and body composition in VLCD treated obesity. DESIGN AND PATIENTS: Fifteen obese women underwent 4 weeks of very low calorie diet (VLCD) in parallel with GH treatment (n = 7) or placebo (n = 8). MEASUREMENTS: Protein metabolism and total glucose turnover were isotopically assayed. Plasma concentrations of amino acids were determined by an HPLC system. Estimated rates of lipid and glucose oxidation were obtained by indirect calorimetry. Fat free mass was determined by DEXA- scan. RESULTS: Protein breakdown decreased in both groups (tyrosine flux μmol/h): -12{\%} ± 3 (GH) vs. -9{\%} ± 3 (placebo)). Phenylalanine degradation in relation to phenylalanine concentration decreased by 9{\%} in the GH group, whereas an increase of 8{\%} was observed in the placebo group (P = 0.1). Plasma concentrations of several amino acids were significantly decreased in the placebo group, while urea excretion decreased in the GH group. A decrease in FFM was found in placebo treated patients (2.14{\%} ± 1.9 (GH) vs. -3.54{\%} ± 1.6 (placebo), P < 0.05). Rates of lipid oxidation tended to be increased by GH treatment (lipid oxidation (mg/minutes): 79.7 ± 5.9 (GH) vs. 64.6 ± 5.9 (placebo), P = 0.1). CONCLUSION: During dietary restriction GH primarily seems to conserve protein by a reduced hepatic degradation of amino acids.",
author = "Helene N{\o}rrelund and Jens B{\o}rglum and J{\o}rgensen, {Jens Otto Lunde} and Bj{\o}rn Richelsen and Niels M{\o}ller and Nair, {K Sreekumaran} and Christiansen, {Jens Sandahl}",
year = "2000",
doi = "10.1046/j.1365-2265.2000.00937.x",
language = "English (US)",
volume = "52",
pages = "305--312",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Effects of growth hormone administration on protein dynamics and substrate metabolism during 4 weeks of dietary restriction in obese women

AU - Nørrelund, Helene

AU - Børglum, Jens

AU - Jørgensen, Jens Otto Lunde

AU - Richelsen, Bjørn

AU - Møller, Niels

AU - Nair, K Sreekumaran

AU - Christiansen, Jens Sandahl

PY - 2000

Y1 - 2000

N2 - OBJECTIVE: Treatment of obesity with very low calorie diet (VLCD) is complicated by protein loss. We evaluated the effects of coadministration of GH on protein turnover, substrate metabolism, and body composition in VLCD treated obesity. DESIGN AND PATIENTS: Fifteen obese women underwent 4 weeks of very low calorie diet (VLCD) in parallel with GH treatment (n = 7) or placebo (n = 8). MEASUREMENTS: Protein metabolism and total glucose turnover were isotopically assayed. Plasma concentrations of amino acids were determined by an HPLC system. Estimated rates of lipid and glucose oxidation were obtained by indirect calorimetry. Fat free mass was determined by DEXA- scan. RESULTS: Protein breakdown decreased in both groups (tyrosine flux μmol/h): -12% ± 3 (GH) vs. -9% ± 3 (placebo)). Phenylalanine degradation in relation to phenylalanine concentration decreased by 9% in the GH group, whereas an increase of 8% was observed in the placebo group (P = 0.1). Plasma concentrations of several amino acids were significantly decreased in the placebo group, while urea excretion decreased in the GH group. A decrease in FFM was found in placebo treated patients (2.14% ± 1.9 (GH) vs. -3.54% ± 1.6 (placebo), P < 0.05). Rates of lipid oxidation tended to be increased by GH treatment (lipid oxidation (mg/minutes): 79.7 ± 5.9 (GH) vs. 64.6 ± 5.9 (placebo), P = 0.1). CONCLUSION: During dietary restriction GH primarily seems to conserve protein by a reduced hepatic degradation of amino acids.

AB - OBJECTIVE: Treatment of obesity with very low calorie diet (VLCD) is complicated by protein loss. We evaluated the effects of coadministration of GH on protein turnover, substrate metabolism, and body composition in VLCD treated obesity. DESIGN AND PATIENTS: Fifteen obese women underwent 4 weeks of very low calorie diet (VLCD) in parallel with GH treatment (n = 7) or placebo (n = 8). MEASUREMENTS: Protein metabolism and total glucose turnover were isotopically assayed. Plasma concentrations of amino acids were determined by an HPLC system. Estimated rates of lipid and glucose oxidation were obtained by indirect calorimetry. Fat free mass was determined by DEXA- scan. RESULTS: Protein breakdown decreased in both groups (tyrosine flux μmol/h): -12% ± 3 (GH) vs. -9% ± 3 (placebo)). Phenylalanine degradation in relation to phenylalanine concentration decreased by 9% in the GH group, whereas an increase of 8% was observed in the placebo group (P = 0.1). Plasma concentrations of several amino acids were significantly decreased in the placebo group, while urea excretion decreased in the GH group. A decrease in FFM was found in placebo treated patients (2.14% ± 1.9 (GH) vs. -3.54% ± 1.6 (placebo), P < 0.05). Rates of lipid oxidation tended to be increased by GH treatment (lipid oxidation (mg/minutes): 79.7 ± 5.9 (GH) vs. 64.6 ± 5.9 (placebo), P = 0.1). CONCLUSION: During dietary restriction GH primarily seems to conserve protein by a reduced hepatic degradation of amino acids.

UR - http://www.scopus.com/inward/record.url?scp=0034105340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034105340&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2265.2000.00937.x

DO - 10.1046/j.1365-2265.2000.00937.x

M3 - Article

C2 - 10718828

AN - SCOPUS:0034105340

VL - 52

SP - 305

EP - 312

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 3

ER -